Protein phosphatase 2A (PP2A) inhibitor CIP2A indicates resistance to radiotherapy in rectal cancer [PDF]
Cancer Medicine, 2018 Preoperative (chemo)radiotherapy, (C)RT, is an essential part of the treatment of rectal cancer patients, but tumor response to this therapy among patients is variable. Thus far, there are no clinical biomarkers that could be used to predict response to (
Eva‐Maria Birkman +8 more
doaj +6 more sources
Prognostic value of CIP2A gene expression in adult Egyptian acute myeloid leukemia patients
Egyptian Journal of Medical Human Genetics, 2020 Background Protein phosphatase 2A (PP2A) functions as a tumor suppressor in many cancers. Cancerous inhibitor of protein phosphatase 2A (CIP2A) inhibits PP2A proteolytic degradation of c-Myc and enhances cell growth and tumor formation in several tissues.
Roxan E. Shafik +5 more
doaj +1 more source
siRNA-Mediated Silencing of CIP2A Enhances Docetaxel Activity Against PC-3 Prostate Cancer Cells [PDF]
Advanced Pharmaceutical Bulletin, 2017 Purpose: Cancerous inhibitor of protein phosphatase 2A (CIP2A) is an identified human oncoprotein which modulates malignant cell growth. It is overexpressed in human prostate cancer and in most of the human malignancies.
Saiedeh Razi Soofiyani +5 more
doaj +1 more source
OCT4 Represses Inflammation and Cell Injury During Orchitis by Regulating CIP2A Expression
Frontiers in Cell and Developmental Biology, 2021 Octamer-binding transcription factor 4 (OCT4) and cancerous inhibitor of protein phosphatase 2A (CIP2A) are upregulated in testicular cancer and cell lines.
Ruifeng Zeng +8 more
doaj +1 more source
CIP2A Promotes T-Cell Activation and Immune Response to Listeria monocytogenes Infection. [PDF]
PLoS ONE, 2016 The oncoprotein Cancerous Inhibitor of Protein Phosphatase 2A (CIP2A) is overexpressed in most malignancies and is an obvious candidate target protein for future cancer therapies. However, the physiological importance of CIP2A-mediated PP2A inhibition is
Christophe Côme +23 more
doaj +1 more source
Journal of Pharmacological Sciences, 2019 Acute myeloid leukemia (AML) is the most common subtype of hematological malignancy in humans, and its incidence increases with age. The treatment of AML still faces challenges.
Wenjing Ma +10 more
doaj +1 more source
CIP2A influences survival in colon cancer and is critical for maintaining Myc expression. [PDF]
PLoS ONE, 2013 The cancerous inhibitor of protein phosphatase 2A (CIP2A) is an oncogenic factor that stabilises the c-Myc protein. CIP2A is overexpressed in several tumours, and expression levels are an independent marker for long-term outcome.
Armin Wiegering +9 more
doaj +1 more source
CIP2A Constrains Th17 Differentiation by Modulating STAT3 Signaling
iScience, 2020 Summary: Cancerous Inhibitor of Protein Phosphatase 2A (CIP2A) is an oncogene and a potential cancer therapy target protein. Accordingly, a better understanding of the physiological function of CIP2A, especially in the context of immune cells, is a ...
Mohd Moin Khan +12 more
doaj +1 more source
Prognostic significance of CIP2A expression in solid tumors: A meta-analysis. [PDF]
PLoS ONE, 2018 CIP2A, cancerous inhibitor of protein phosphatase 2A, was initially recognized as an oncoprotein. Recently several studies revealed that CIP2A could function as a prognosis biomarker, however, the result remained not comprehensive, partly due to small ...
Min Tang +7 more
doaj +1 more source
Reciprocal regulation of CIP2A and AR expression in prostate cancer cells
Discover Oncology, 2022 Cancerous inhibitor of protein phosphatase 2A (CIP2A) is an oncoprotein overexpressed in human malignancies, including prostate cancer (PCa). In this study, we aimed to explore the oncogenic function of CIP2A in PCa cells and its underlying mechanism. We
Hao-Wen Chuang +10 more
doaj +1 more source